<<Disclaimer: Verify this information before applying it to your situation.>>

After learning about Paneth cells and their symbiotic relationship with the
bacteria, Bacteroides thetaiotaomicron, I wondered if there was a probiotic
containing B. thetaiotaomicron.  I found none in a web search, but I did
come across this U.S. Patent Application.  It seems there is already a lock
on the concept of a B. thetaiotaomicron probiotic.  I don't know what this
will mean as to when such a probiotic might become available, but clearly
there is a promising therapeutic value for such a probiotic for treating
the small intestine when under attack.  It might help to recover from CD,
heal the intestine and restore the balance of good intestinal flora.


Gut Bacteria Interact with Intestine to Regulate Blood Supply (Nov. 4, 2002)
http://mednews.wustl.edu/medadmin/PAnews.nsf/0/B14C4FCB1C4037CA86256C67007DF
1A2

Search and Destroy: Newly Identified Gut Protein Kills Bacteria (Jan. 26,
2003)
http://mednews.wustl.edu/medadmin/PAnews.nsf/0/7BF498C3BA91B68586256CB8007C7
B81


---------------------------------------------------------------------
United States Patent Application 20030133875
Kind Code  A1
Kelly, Denise  July 17, 2003

---------------------------------------------------------------------
Assay for screening candidate drug for the treatment of inflammatory
diseases and methods for treating the same


Abstract
The invention relates to an assay to select a candidate drug for the
treatment of inflammatory disease due to cytokine production. The assay
comprises: a) exposing said candidate drug to intestinal cells; and b)
analysing the effect of the said candidate drug selected from the group
consisting of the variation of nuclear export or import of transcription
factors from the NF-.kappa.B family the disruption of transcriptional
activity of transcription factors from the NF-.kappa.B family, the
differential histone acetylation of p65 (RelA); the variation of the amount
of PPAR.gamma./RelA complexes in the cytosol of the cells; and a
combination thereof. The invention further relates to methods for the
treatment of inflammatory cytokine production associated diseases and to
the use of a therapeutically effective dose of Bacteroides thetaiotaomicron
or a component thereof.


---------------------------------------------------------------------
Inventors: Kelly, Denise; (Kingswell, GB)
Correspondence Name and Address:      DRINKER BIDDLE & REATH
    ONE LOGAN SQUARE
    18TH AND CHERRY STREETS
    PHILADELPHIA
    PA
    19103-6996
    US


Assignee Name and Adress: Rowett Research Institute
Grenburn Road
Bucksburn
GB
AB15 8TT


Serial No.:  285224
Series Code:  10
Filed:  October 31, 2002

U.S. Current Class: 424/9.2; 424/93.4; 435/7.2; 435/7.32
U.S. Class at Publication: 424/9.2; 424/93.4; 435/7.2; 435/7.32
Intern'l Class:  A61K 049/00; A61K 045/00; G01N 033/53; G01N 033/567; G01N
033/554; G01N 033/569



----------------------------------------------------------------------

Foreign Application Data

----------------------------------------------------------------------
Date Code Application Number
Nov 21, 2001 GB 0127916.5

----------------------------------------------------------------------

Claims

----------------------------------------------------------------------

[Claims 1. - 16. omitted for brevity.]

17. A method of treating the inflammatory response of intestinal cells,
said method comprising the step of administering a therapeutically
effective dose of Bacteroides thetaiotaomicron or a component thereof.

18. The method of claim 17 wherein said Bacteroides thetaiotaomicron are
administered live to a patient by means of a foodstuff or suppository.

19. The method of claim 17 for the treatment of inflammatory cytokine
production associated diseases.

20. The method of claim 17 wherein said diseases are selected from the
group consisting of inflammatory bowel disease; Crohn's disease; Irritable
Bowel Syndrome; rheumatoid arthritis; immunodeficiency syndrome; cachexia;
multiple sclerosis, inhibition of proliferation of keratinocytes;
inhibition of hyperproliferative; inflammatory disorders of the skin;
psoriasis and acne vulgaris.

21. The method of claim 17 wherein the therapeutically effective dose of
Bacteroides thetaiotaomicron or a component thereof is delivered orally.

* * *

*Support summarization of posts, reply to the SENDER not the CELIAC List*